SE459920B - Estrar av 4-(2-(2-karboxietenyl)fenyl)-dihydropyridindikarboxylsyror, foerfarande foer framstaellning av dessa och en farmaceutisk komposition - Google Patents

Estrar av 4-(2-(2-karboxietenyl)fenyl)-dihydropyridindikarboxylsyror, foerfarande foer framstaellning av dessa och en farmaceutisk komposition

Info

Publication number
SE459920B
SE459920B SE8503888A SE8503888A SE459920B SE 459920 B SE459920 B SE 459920B SE 8503888 A SE8503888 A SE 8503888A SE 8503888 A SE8503888 A SE 8503888A SE 459920 B SE459920 B SE 459920B
Authority
SE
Sweden
Prior art keywords
formula
ester
group
dimethyl
alkyl group
Prior art date
Application number
SE8503888A
Other languages
English (en)
Swedish (sv)
Other versions
SE8503888L (sv
SE8503888D0 (sv
Inventor
C Semeraro
D Micheli
D Pieraccioli
G Gaviraghi
A D Borthwick
Original Assignee
Glaxo Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from IT22383/84A external-priority patent/IT1175620B/it
Priority claimed from IT21460/85A external-priority patent/IT1187678B/it
Application filed by Glaxo Spa filed Critical Glaxo Spa
Publication of SE8503888D0 publication Critical patent/SE8503888D0/xx
Publication of SE8503888L publication Critical patent/SE8503888L/xx
Publication of SE459920B publication Critical patent/SE459920B/sv

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/90Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/08Vasodilators for multiple indications
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C03GLASS; MINERAL OR SLAG WOOL
    • C03BMANUFACTURE, SHAPING, OR SUPPLEMENTARY PROCESSES
    • C03B2205/00Fibre drawing or extruding details
    • C03B2205/44Monotoring or regulating the preform feed rate

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
SE8503888A 1984-08-22 1985-08-20 Estrar av 4-(2-(2-karboxietenyl)fenyl)-dihydropyridindikarboxylsyror, foerfarande foer framstaellning av dessa och en farmaceutisk komposition SE459920B (sv)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT22383/84A IT1175620B (it) 1984-08-22 1984-08-22 Derivati piridinici
IT21460/85A IT1187678B (it) 1985-07-05 1985-07-05 Procedimento di preparazione di derivati eterociclici

Publications (3)

Publication Number Publication Date
SE8503888D0 SE8503888D0 (sv) 1985-08-20
SE8503888L SE8503888L (sv) 1986-02-23
SE459920B true SE459920B (sv) 1989-08-21

Family

ID=26327905

Family Applications (1)

Application Number Title Priority Date Filing Date
SE8503888A SE459920B (sv) 1984-08-22 1985-08-20 Estrar av 4-(2-(2-karboxietenyl)fenyl)-dihydropyridindikarboxylsyror, foerfarande foer framstaellning av dessa och en farmaceutisk komposition

Country Status (33)

Country Link
US (2) US4801599A (fi)
JP (2) JPS6193162A (fi)
KR (1) KR920004482B1 (fi)
AT (1) AT394042B (fi)
AU (1) AU578724B2 (fi)
BE (1) BE903103A (fi)
BG (1) BG60409B2 (fi)
CA (1) CA1268180A (fi)
CH (1) CH666684A5 (fi)
CS (1) CS403091A3 (fi)
CY (1) CY1494A (fi)
DE (1) DE3529997C2 (fi)
DK (1) DK165949C (fi)
ES (5) ES8703839A1 (fi)
FI (1) FI81568C (fi)
FR (1) FR2569402B1 (fi)
GB (1) GB2164336B (fi)
GR (1) GR852016B (fi)
HK (1) HK52990A (fi)
HU (1) HU196754B (fi)
IE (1) IE58486B1 (fi)
LU (2) LU86047A1 (fi)
MX (1) MX159974A (fi)
NL (2) NL193065C (fi)
NO (2) NO167142C (fi)
NZ (1) NZ212895A (fi)
PH (1) PH22014A (fi)
PT (1) PT81000B (fi)
SA (1) SA91120277B1 (fi)
SE (1) SE459920B (fi)
SG (1) SG40889G (fi)
SK (1) SK278327B6 (fi)
ZW (1) ZW13185A1 (fi)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ212895A (en) * 1984-08-22 1988-07-28 Glaxo Spa 1,4-dihydropyridine derivatives and pharmaceutical compositions
EP0226271B1 (en) * 1985-08-21 1990-11-22 GLAXO S.p.A. 1,4-dihydropyridine compounds and their preparation and pharmaceutical formulation
NZ217282A (en) * 1985-08-21 1989-01-27 Glaxo Spa 1,4-dihydropyridine derivatives and pharmaceutical compositions
IT1204460B (it) * 1986-02-20 1989-03-01 Glaxo Spa Derivati eterociclici
IT1204461B (it) * 1986-02-20 1989-03-01 Glaxo Spa Derivati eterociclici
IT1204462B (it) * 1986-02-20 1989-03-01 Glaxo Spa Derivati eterociclici
IT1233370B (it) * 1988-11-21 1992-03-27 Glaxo Spa Procedimento di preparazione di derivati diidropipiridinici utili nel trattamento di disturbi cardiovascolari
EP0395369B1 (en) 1989-04-27 1997-07-02 Canon Inc. Optical recording medium and process for production thereof
US5177202A (en) * 1990-10-09 1993-01-05 Merck & Co., Inc. 2-phenanthrenyl-carbapenems
US5196529A (en) * 1990-10-09 1993-03-23 Merck & Co., Inc. 2-phenanthrenyl carbapenem intermediates
US5132421A (en) * 1990-10-09 1992-07-21 Merck & Co., Inc. 2-naphthyl-carbapenem intermediates
US5132422A (en) * 1990-10-09 1992-07-21 Merck & Co., Inc. 2-naphthyl-carbapenem intermediates
US5144028A (en) * 1990-10-09 1992-09-01 Merck & Co., Inc. 2-(9-fluorenonyl)-carbapenem intermediates
US5356889A (en) * 1990-08-01 1994-10-18 Merck & Co., Inc. 2-(9-fluorenonyl)-carbapenem intermediates
US5208329A (en) * 1990-10-09 1993-05-04 Merck & Co., Inc. 2-biphenyl carbapenem intermediates
IT1244728B (it) * 1991-02-13 1994-08-08 Glaxo Spa Impiego medicamentoso di derivati diidropiridinici
TW483763B (en) * 1994-09-02 2002-04-21 Astra Ab Pharmaceutical composition comprising of ramipril and dihydropyridine compound
AU1042199A (en) * 1998-11-06 2000-05-29 Boehringer Ingelheim International Gmbh Antihypertensive medicaments containing lacidipine and telmisartan
CN1681495B (zh) 2002-08-19 2010-05-12 辉瑞产品公司 用于治疗过度增生性疾病的组合物
KR20110117731A (ko) * 2003-05-30 2011-10-27 랜박시 래보러터리스 리미티드 치환된 피롤 유도체와 hmg―co 억제제로서의 이의 용도
US20050037063A1 (en) * 2003-07-21 2005-02-17 Bolton Anthony E. Combined therapies
KR20070054644A (ko) * 2004-07-26 2007-05-29 액테리온 파마슈티칼 리미티드 미립자 제형으로 흡입된 일로프로스트에 의한 폐고혈압의치료
WO2006113309A1 (en) 2005-04-15 2006-10-26 Dr. Reddy's Laboratories Ltd. Lacidipine particles
US20070043088A1 (en) * 2005-08-16 2007-02-22 Eswaraiah Sajja Process for preparing lacidipine
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
EP2351569B1 (en) 2005-10-26 2012-08-22 Asahi Kasei Pharma Corporation Fasudil in combination therapies for the treatment of pulmonary arterial hypertension
ATE551059T1 (de) 2005-10-26 2012-04-15 Asahi Kasei Pharma Corp Fasudil in kombination mit bosentan zur behandlung von pulmonaler arterieller hypertonie
AU2006313430B2 (en) * 2005-11-08 2012-09-06 Ranbaxy Laboratories Limited Process for (3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4- [(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3, 5-dihydroxy-heptanoic acid hemi calcium salt
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
US7919506B2 (en) 2006-03-10 2011-04-05 Pfizer Inc. Dibenzyl amine compounds and derivatives
WO2008020314A2 (en) * 2006-03-14 2008-02-21 Ranbaxy Laboratories Limited Statin stabilizing dosage formulations
WO2008010087A2 (en) * 2006-07-14 2008-01-24 Ranbaxy Laboratories Limited Polymorphic forms of an hmg-coa reductase inhibitor and uses thereof
US20080089947A1 (en) * 2006-08-18 2008-04-17 Knox Clayton D Calcium Influx Inhibitors in the Treatment of Ischemia
JP5498168B2 (ja) 2006-12-01 2014-05-21 ブリストル−マイヤーズ スクイブ カンパニー アテローム性動脈硬化および循環器疾患の治療のためのcetp阻害剤としてのn−((3−ベンジル)−2,2−(ビス−フェニル)−プロパン−1−アミン誘導体
WO2012037665A1 (en) 2010-09-24 2012-03-29 Oral Delivery Technology Ltd. Nitric oxide releasing amino acid ester for treatment of pulmonary hypertension and other respiratory conditions
PL2705839T3 (pl) 2012-09-10 2018-07-31 Rivopharm Sa Farmaceutyczna kompozycja zawierająca lacydypinę i proces przygotowania
EP2986599A1 (en) 2013-04-17 2016-02-24 Pfizer Inc. N-piperidin-3-ylbenzamide derivatives for treating cardiovascular diseases
WO2016055901A1 (en) 2014-10-08 2016-04-14 Pfizer Inc. Substituted amide compounds
BR112021013807A2 (pt) 2019-01-18 2021-11-30 Astrazeneca Ab Inibidores de pcsk9 e seus métodos de uso

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3455945A (en) * 1967-06-07 1969-07-15 Smithkline Corp 4-(carboxy (and carbo-lower alkoxy)phenyl)-1,4-dihydropyridines
DE2228363A1 (de) * 1972-06-10 1974-01-03 Bayer Ag 1,4-dihydropyridine, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel
GB1409865A (en) * 1973-02-13 1975-10-15 Science Union & Cie Dihydropyridines derivatives their preparation and pharmaceu tical compositions containing them
US4307103A (en) * 1978-09-08 1981-12-22 Fujisawa Pharmaceutical Co., Ltd. Dihydropyridine derivative, processes for preparation thereof and pharmaceutical composition comprising the same
DE3018259A1 (de) * 1980-05-13 1981-11-19 Bayer Ag, 5090 Leverkusen 1,4-dihydropyridine mit unterschiedlichen substituenten in 2- und 6-position, verfahren zu ihrer herstellung und ihre verwendung in arzneimitteln
NZ201395A (en) * 1981-07-30 1987-02-20 Bayer Ag Pharmaceutical compositions containing 1,4-dihydropyridines and certain of these dihydropyridines
DE3207982A1 (de) * 1982-03-05 1983-09-08 Bayer Ag, 5090 Leverkusen Neue 1,4-dihydropyridine, verfahren zu ihrer herstellung und ihrer verwendung in arzneimitteln
NZ212895A (en) * 1984-08-22 1988-07-28 Glaxo Spa 1,4-dihydropyridine derivatives and pharmaceutical compositions

Also Published As

Publication number Publication date
FI853206L (fi) 1986-02-23
ES8703839A1 (es) 1987-03-01
ES8707932A1 (es) 1987-09-01
CA1268180A (en) 1990-04-24
DE3529997A1 (de) 1986-03-06
DK165949C (da) 1993-07-05
FI81568C (fi) 1990-11-12
BE903103A (fr) 1986-02-24
SK278327B6 (en) 1996-11-06
IE852054L (en) 1986-02-22
ES552050A0 (es) 1987-09-01
HU196754B (en) 1989-01-30
ES8707930A1 (es) 1987-09-01
KR870002073A (ko) 1987-03-28
DK378085A (da) 1986-02-23
LU88267I2 (fi) 1994-02-03
NO167142B (no) 1991-07-01
JPS6479152A (en) 1989-03-24
CS403091A3 (en) 1992-06-17
HK52990A (en) 1990-07-20
ES8802497A1 (es) 1988-07-01
NL193065B (nl) 1998-05-06
PT81000A (en) 1985-09-01
KR920004482B1 (ko) 1992-06-05
GB2164336B (en) 1988-06-08
SE8503888L (sv) 1986-02-23
ES552051A0 (es) 1987-09-01
LU86047A1 (fr) 1986-02-28
JPH0550506B2 (fi) 1993-07-29
AT394042B (de) 1992-01-27
NL193065C (nl) 1998-09-08
SA91120277B1 (ar) 2006-05-15
FI81568B (fi) 1990-07-31
GB2164336A (en) 1986-03-19
HUT40625A (en) 1987-01-28
IE58486B1 (en) 1993-09-22
NZ212895A (en) 1988-07-28
AU4657685A (en) 1986-02-27
NO853293L (no) 1986-02-24
DK378085D0 (da) 1985-08-20
ZW13185A1 (en) 1986-03-19
GR852016B (fi) 1985-12-19
MX159974A (es) 1989-10-17
PT81000B (pt) 1988-03-03
ATA245485A (de) 1991-07-15
CY1494A (en) 1990-02-16
ES546324A0 (es) 1987-03-01
US4801599A (en) 1989-01-31
SG40889G (en) 1989-12-22
CH666684A5 (de) 1988-08-15
JPH0686430B2 (ja) 1994-11-02
NL980037I1 (nl) 1999-02-01
FR2569402B1 (fr) 1989-09-22
NO1999007I1 (no) 1999-04-23
ES8707931A1 (es) 1987-09-01
PH22014A (en) 1988-05-02
NL8502296A (nl) 1986-03-17
NO167142C (no) 1991-10-09
FR2569402A1 (fr) 1986-02-28
ES552049A0 (es) 1988-07-01
ES552048A0 (es) 1987-09-01
GB8520924D0 (en) 1985-09-25
DK165949B (da) 1993-02-15
JPS6193162A (ja) 1986-05-12
DE3529997C2 (de) 1996-01-18
FI853206A0 (fi) 1985-08-21
NL980037I2 (nl) 1999-03-01
BG60409B2 (bg) 1995-02-28
US5011848A (en) 1991-04-30
AU578724B2 (en) 1988-11-03
SE8503888D0 (sv) 1985-08-20

Similar Documents

Publication Publication Date Title
SE459920B (sv) Estrar av 4-(2-(2-karboxietenyl)fenyl)-dihydropyridindikarboxylsyror, foerfarande foer framstaellning av dessa och en farmaceutisk komposition
JPH06234741A (ja) 置換4−フエニルピリドン及び4−フエニル−2−アルコキシピリジン
CH633266A5 (en) Process for preparing 1,4-dihydropyridine compounds
TW201639820A (zh) 二氫嘧啶-2-酮化合物及其醫藥用途
US4829081A (en) Analogs of mevalonolactone and derivatives thereof
HU208691B (en) Method for producing disubstituted pyridine derivatives and medical preparatives containing them
US4946851A (en) 1.4-dihydropyridines
US4963571A (en) Pyridinedicarboxylic acid derivatives and pharmaceutical compositions
EP0226271B1 (en) 1,4-dihydropyridine compounds and their preparation and pharmaceutical formulation
US5162345A (en) Heterocyclic compounds and their preparation and pharmaceutical formulation
KR950011410B1 (ko) 헤테로사이클릭 화합물의 제조방법
AU707289B2 (en) Method of preparing phosphodiesterase IV inhibitors
NO174419B (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive heterocykliske forbindelser
EP0242950A2 (en) dihydropyridines, process for their preparation and their use as therapeutics
JPS6296468A (ja) 複素環式化合物およびそれらの製造ならびに医薬製剤

Legal Events

Date Code Title Description
NAL Patent in force

Ref document number: 8503888-3

Format of ref document f/p: F

SPCF Application for supplementary protection certificate filed

Free format text: 9790041, 970613

SPCG Supplementary protection certificate granted

Free format text: 9790041, 970613, EXPIRES: 20051106

NUG Patent has lapsed